Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.

As federal scrutiny and legislative proposals continue around the 340B drug pricing program, health systems are stepping up advocacy efforts and preparing for potential disruptions. At St. Louis-based ...

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...

Drugmakers say they’re trying to crack down on abuse in the 340B program, which was established more than three decades ago in order to make it easier for hospitals serving more vulnerable populations ...

The Health Resources & Services Administration has told Johnson & Johnson it cannot use a rebate model to replace upfront discounts in its 340B drug pricing program, according to the American Hospital ...

Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to ...

The 340B Drug Pricing Program is a federal lifeline for vulnerable and underserved communities across the U.S., and its importance in Orlando is profound. Created to allow health-care safety-net ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...